asa glp 1 guidelines New therapeutic agents for type 2 diabetes: anaesthetic considerations. A narrative review aGLP-1 receptor agonists & anesthesia:

Bioengineered (2021) 12(2):1212334

Clinical evidence shows LDL reductions of 510% and triglyceride improvements of 1525% in most patients, with better results in those who achieve significant weight loss

Taken together, these findings indicate the large variability in the cAMP responses these poly-ligands induce, which, in turn, may explain clinical differences among them, such as the very recently reported differences in their clinical efficacies at reducing body weight, with retatrutide appearing the most effective agent (producing a ~24% weight loss, almost equivalent to surgical interventions) [58]

Also an increase in M2 (Cd206 + ) subpopulation, concomitantly with a decrease in M1 (Cd11c + ) cells gated from the macrophages (Cd11b + F4/80 + ) (Fig

Lassailly G, Caiazzo R, Buob D, et al